In response to a significant shortage of ADHD medications, the DEA has approved a 24% increase in production for Takeda Pharmaceuticals' Vyvanse and its generic versions. This decision follows a request from the FDA in July and aims to address both domestic and international demand exacerbated by manufacturing delays and rising consumption. Lisdexamfetamine, the active ingredient in Vyvanse, is classified as a Schedule II controlled substance, requiring strict prescribing safeguards due to its potential for abuse. The increased production includes an additional 6,236 kilograms of lisdexamfetamine, with 1,558 kilograms allocated for U.S. needs and 4,678 kilograms for global markets. The FDA has also approved generic versions of Vyvanse from 11 manufacturers to stabilize supply post-Takeda's exclusivity. This move seeks to ensure an adequate and uninterrupted supply of ADHD medications for patients worldwide.